COMMUNIQUÉS West-GlobeNewswire

FDA Grants Fast Track Designation to SOTIO’s SOT106 ADC for Soft Tissue Sarcoma Treatment, Accelerating Clinical Development
26/08/2026
SOT106 targets LRRC15, a clinically validated target broadly expressed across multiple sarcoma subtypes First-in-human study expected to begin this year, marking a key development milestone for SOT106 PRAGUE, Basel and [...]
Odyssey Therapeutics to Participate in Upcoming Investor Conferences
26/08/2026
BOSTON, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients [...]
BridgeBio Announces First Participant Dosed in ASCEND-ATTR, a Phase 3b/4 Study Evaluating the Long-Term Effects of Acoramidis on Disease Regression in ATTR-CM
26/08/2026
- The ASCEND-ATTR study builds on the Phase 3 ATTRibute-CM CMR substudy results previously shared here , which indicated treatment with acoramidis may improve cardiac structure and function with evidence of amyloid [...]
Eikon Therapeutics to Participate in Investor Conferences in September 2026
26/08/2026
MILLBRAE, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious [...]
MicrobiotiX Completes Sentinel Cohort of its First-in-human Clinical Trial of MP101 for Pneumonia
26/08/2026
Photo Caption: Dr. Dongeun Yong, CEO, gives a tour of MicrobiotiX’s GMP facility, where the clinical material being used in the MP101 trial was manufactured. SEOUL, South Korea, Aug. 26, 2026 (GLOBE NEWSWIRE) -- [...]
Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026
26/08/2026
Professor Marlies Wijsenbeek will give an oral presentation on the quality-of-life outcomes assessed by the LCQ from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-related chronic cough [...]
Repligen Corporation to Present at Wells Fargo 21st Annual Healthcare Conference
26/08/2026
WALTHAM, Mass., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the Wells Fargo [...]
Wellness Together and TadHealth Partner to Expand Student Behavioral Health Support Through CYBHI
26/08/2026
Partnership helps California schools and community-based organizations simplify CYBHI participation while expanding access to behavioral health services for students NEWPORT BEACH, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE [...]
Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors
26/08/2026
Doses first patient at 70 mCi dose of RV-01, the first radiopharmaceutical therapeutic developed in Company’s joint venture with MD Anderson Cancer Center SYDNEY, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Radiopharm [...]
Ligand to Participate in September Investor Conferences
26/08/2026
JUPITER, Fla., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced its senior management team will participate in the following upcoming investor conferences: Wells Fargo [...]
INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings
26/08/2026
Orphan Drug Designation application and pre-MAA Scientific Advice package submitted for Ebstrocel™ in RDEB Filings support a planned EU MAA in Q1 2027; orphan designation, if granted and maintained through approval, may [...]
Kestra Appoints Curtis Kopf as Senior Vice President of Customer Experience
26/08/2026
KIRKLAND, Wash., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today announced the appointment of Curtis Kopf as [...]
HepaRegeniX Receives Orphan Drug Designation for Darizmetinib for the Prevention of Post-Hepatectomy Liver Failure
26/08/2026
U.S. FDA Orphan Drug Designation underscores darizmetinib’s potential to address a significant unmet need following liver resection Tuebingen, Germany, August 26, 2026 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical- [...]
Nxera Pharma’s Partner Neurocrine Biosciences Receives IND Acceptance from the FDA for Phase 2 Study of NBI-1117567 for Alzheimer's Cognition
26/08/2026
NBI-1117567 is an investigational oral, muscarinic M1 preferring (M1/M4) selective agonist discovered by Nxera and advancing through clinical development under a multi-program collaboration with Neurocrine Nxera to [...]
4basebio and Genezen Enter into Strategic Collaboration to Advance Synthetic, Cell-Free DNA Platforms for Next-Generation Viral Vector Manufacturing
26/08/2026
Commercial collaboration combines 4basebio’s synthetic DNA technology with Genezen’s viral vector development and manufacturing expertise to support gene therapy programs from early development through clinical and [...]
ADDEX raises USD 2.8 million through its ATM agreement and extends cash runway to the fourth quarter 2027
26/08/2026
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 26, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small [...]
Testie Health Launches Nationwide to Make STI Testing Simpler, Faster, and Less Stigmatized
26/08/2026
New York, NY, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Testie Health , a consumer health company focused on making routine STI testing easier and less stigmatized, launches nationwide with a direct-to-lab testing model [...]
Celularity Provides Update Regarding Nasdaq Listing Compliance
26/08/2026
FLORHAM PARK, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”) today announced that, on August 21, 2026, it received a notification letter from the Listing Qualifications Department [...]
SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
26/08/2026
JERSEY CITY, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX), a clinical-stage biotechnology company focused on developing innovative therapies for severe and difficult-to-treat diseases with [...]

Pages